BIOMAT Database Logo BIOMAT Database Logo

Endogenous marinobufagenin-like immunoreactive substance. A possible endogenous Na, K-ATPase inhibitor with vasoconstrictor activity. 1996

A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
Laboratory of Pharmacology, I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia.

Vasoconstrictor and Na/K pump inhibitory properties of a bufodienolide Na/K-ATPase inhibitor, marinobufagenin, were studied in isolated rings of 2 to 3 order branches of human pulmonary arteries respectively. Marinobufagenin displayed concentration-dependent vasoconstrictor activity (0.01 to 10 mmol/L). In sarcolemma membranes prepared from pulmonary artery marinobufagenin inhibited Na/K-ATPase (IC50 = 50 nmol/L). In eight healthy male Caucasians, concentrations of marinobufagenin-like immunoreactive material in C-18 extracted plasma were 1.38 +/- 0.60 nmol/L. Twenty-four-hour urinary release of marinobufagenin-like immunoreactive material in eight healthy males was 1.20 +/- 0.95 nmol/day. Chloroform extract of human urine was fractionated using reverse-phase high-performance liquid chromatography (32% acetonitrile, Deltapak). The HPLC fraction coeluting with marinobufagenin in 7 min, cross reacted with antimarinobufagenin and antidigoxin, but not antiouabain antibody. These results demonstrate that human plasma and urine contains a bufodienolide vasoconstrictor EDLF, marinobufagenin-like immunoreactive Na,K pump inhibitor.

UI MeSH Term Description Entries
D008297 Male Males
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D002018 Bufanolides Cyclopentanophenanthrenes with a 6-membered lactone ring attached at the 17-position and SUGARS attached at the 3-position. They are found in BUFONIDAE and often possess cardiotonic properties. Bufadienolides
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000254 Sodium-Potassium-Exchanging ATPase An enzyme that catalyzes the active transport system of sodium and potassium ions across the cell wall. Sodium and potassium ions are closely coupled with membrane ATPase which undergoes phosphorylation and dephosphorylation, thereby providing energy for transport of these ions against concentration gradients. ATPase, Sodium, Potassium,Adenosinetriphosphatase, Sodium, Potassium,Na(+)-K(+)-Exchanging ATPase,Na(+)-K(+)-Transporting ATPase,Potassium Pump,Sodium Pump,Sodium, Potassium ATPase,Sodium, Potassium Adenosinetriphosphatase,Sodium-Potassium Pump,Adenosine Triphosphatase, Sodium, Potassium,Na(+) K(+)-Transporting ATPase,Sodium, Potassium Adenosine Triphosphatase,ATPase Sodium, Potassium,ATPase, Sodium-Potassium-Exchanging,Adenosinetriphosphatase Sodium, Potassium,Pump, Potassium,Pump, Sodium,Pump, Sodium-Potassium,Sodium Potassium Exchanging ATPase,Sodium Potassium Pump
D014661 Vasoconstriction The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE. Vasoconstrictions
D014662 Vasoconstrictor Agents Drugs used to cause constriction of the blood vessels. Vasoactive Agonist,Vasoactive Agonists,Vasoconstrictor,Vasoconstrictor Agent,Vasoconstrictor Drug,Vasopressor Agent,Vasopressor Agents,Vasoconstrictor Drugs,Vasoconstrictors,Agent, Vasoconstrictor,Agent, Vasopressor,Agents, Vasoconstrictor,Agents, Vasopressor,Agonist, Vasoactive,Agonists, Vasoactive,Drug, Vasoconstrictor,Drugs, Vasoconstrictor

Related Publications

A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
[Endogenous digitalis-like substance and Na-K-ATPase inhibitor in cardiovascular and renal disease].
January 1988, Nihon Naibunpi Gakkai zasshi,
A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
Phorbol diacetate potentiates na(+)-k(+) ATPase inhibition by a putative endogenous ligand, marinobufagenin.
February 2002, Hypertension (Dallas, Tex. : 1979),
A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
Marinobufagenin, an endogenous inhibitor of alpha-1 Na/K-ATPase, is a novel factor in pathogenesis of diabetes mellitus.
January 2005, Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections,
A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
Biological activity of partially purified digitalis-like substance and Na-K-ATPase inhibitor in rats.
November 1988, Japanese circulation journal,
A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
Na+,K+-ATPase interaction with a brain endogenous inhibitor (endobain E).
November 1998, Neurochemistry international,
A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
Specific endogenous Na, K-ATPase inhibitor purified from bovine adrenal.
December 1987, Biochemical and biophysical research communications,
A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
Ascorbic acid: an endogenous inhibitor of isolated Na+,K+-ATPase.
July 1985, Biochemical pharmacology,
A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
Digoxin-like immunoreactivity of a circulating (Na+ + K+)ATPase inhibitor.
January 1983, Nature,
A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
The Na+K+-ATPase Inhibitor Marinobufagenin and Early Cardiovascular Risk in Humans: a Review of Recent Evidence.
April 2019, Current hypertension reports,
A Y Bagrov, and R I Dmitrieva, and O V Fedorova, and G P Kazakov, and N I Roukoyatkina, and V M Shpen
Elevated endogenous Na-K-ATPase inhibitor activity in hypertensive diabetic patients with a family history of hypertension.
January 1991, The Journal of diabetic complications,
Copied contents to your clipboard!